Ketamine Troches for Anxiety Disorders

Ketamine Troches for Anxiety: An Evolving Treatment Option

Ketamine troches for anxiety are sublingual lozenges that dissolve under the tongue, delivering ketamine into the bloodstream for patients whose anxiety hasn't responded to standard treatment. Anxiety disorders affect approximately 18 percent of adults in the United States each year, according to the National Institute of Mental Health. Despite a range of treatment options, including SSRIs, SNRIs, benzodiazepines, buspirone, and psychotherapy, a significant subset of patients achieve only partial relief or don't respond at all.

Ketamine's relationship with anxiety is more complicated than its relationship with depression. At higher doses, especially during onset, ketamine can temporarily increase anxiety as a side effect. At therapeutic doses with proper preparation, it has shown meaningful anxiolytic effects in clinical settings. For anxiety disorders that haven't responded to conventional treatment, ketamine troches offer a low-cost, at-home option worth understanding in detail, starting with how the safety profile differs from depression protocols.

Which Anxiety Disorders Respond to Ketamine?

Generalized Anxiety Disorder (GAD)

GAD involves persistent, excessive worry across multiple areas of life, along with physical symptoms such as muscle tension, restlessness, and difficulty sleeping. The glutamate system plays a significant role in anxiety: hyperactive signaling at the NMDA receptor, a glutamate receptor central to learning, memory, and pain processing, is associated with pathological fear and worry in the amygdala and prefrontal cortex. Ketamine's NMDA receptor blockade modulates this hyperactivity, reducing the neural noise that underlies chronic worry. Observational studies and case series report meaningful reductions in GAD symptoms following ketamine treatment, particularly in patients who haven't responded to SSRIs or SNRIs.

Social Anxiety Disorder (SAD)

Social anxiety involves intense fear of social scrutiny, humiliation, or embarrassment, often leading to avoidance of social situations. Formal clinical trials of ketamine specifically for SAD are limited, but a few mechanisms suggest potential benefit:

• Reduction in threat sensitivity and emotional reactivity
• Modulation of the default mode network, which can quiet the self-critical internal monologue characteristic of social anxiety
• Ego-softening effects during sessions that may allow patients to reframe how they appraise social threats

PTSD

Post-traumatic stress disorder is technically a trauma-related disorder rather than a pure anxiety disorder under DSM-5 criteria, but it shares significant symptom overlap with anxiety. Ketamine's specific mechanisms relevant to PTSD are covered in our guide to ketamine troches for PTSD.

Comorbid Anxiety with Depression

The most common clinical presentation for ketamine-treated anxiety isn't a pure anxiety disorder, but anxiety that occurs alongside depression. Because ketamine's antidepressant effects are well established, and depression and anxiety commonly co-occur, many patients treated for treatment-resistant depression also report meaningful improvement in their anxiety symptoms. Two oral ketamine trials illustrate this pattern: Arabzadeh et al. (2018) combined 50 mg oral ketamine with sertraline and found separation from placebo within two weeks, and Jafarinia et al. (2018) tested 150 mg daily oral ketamine against placebo over six weeks with a positive result. Both were designed primarily as depression trials, but the anxiety-reduction pattern they document is consistent with what providers report clinically.

Mechanism: How Ketamine Reduces Anxiety

NMDA Receptor Modulation in Fear Circuitry

The amygdala, the brain's threat detection center, expresses high concentrations of NMDA receptors. Pathological anxiety is associated with hyperactivation of amygdala-based fear circuits. Ketamine blocks NMDA receptors, reducing this hyperactivation and potentially disrupting entrenched fear memories. This mechanism is closely related to how ketamine is thought to affect PTSD, where disrupting fear memory reconsolidation, the process of updating a fear memory each time it's retrieved, may play a role. More on ketamine's pharmacology is available from StatPearls.

Default Mode Network Modulation

The default mode network (DMN) is a set of brain regions active during self-referential thought, rumination, and mind-wandering, and it's hyperactive in both depression and anxiety. Ketamine disrupts DMN hyperconnectivity, producing the ego-softening and reduced self-referential processing that characterizes its subjective effects. For anxiety, this disruption may temporarily reduce the capacity for anticipatory worry, which is largely DMN-mediated, creating a window to engage with anxiety from a less reactive stance.

BDNF and Neuroplasticity

As with depression, ketamine's induction of brain-derived neurotrophic factor (BDNF), a protein that supports neuron growth and new synaptic connections, and the synaptogenesis that follows in prefrontal areas supports top-down regulation of anxiety. The prefrontal cortex normally provides inhibitory control over amygdala reactivity; in chronic anxiety, that top-down regulation is impaired. Ketamine's neuroplastic effects may help restore it.

Clinical Protocols for Anxiety

Assessment

Before starting treatment, most providers will:

• Complete a GAD-7 (a seven-item questionnaire used to screen and track generalized anxiety severity) or DASS-Anxiety scale at baseline
• Discuss the potential for ketamine to temporarily increase anxiety during sessions
• Review grounding techniques for managing anxiety during onset
• Confirm there's no history of panic disorder that could predispose a patient to panic attacks during the dissociative state

Starting Dose for Anxiety Patients

Lower starting doses are generally recommended for anxiety patients than for depression alone. Initial doses typically start at 50-100 mg, with smaller titration increments (25 mg rather than 50 mg) and a target therapeutic range of 150-250 mg, often lower than the depression range, reflecting greater sensitivity to onset effects. See our guide on sublingual versus buccal placement for how administration route affects onset and intensity, and our onset, peak, and duration timeline for what to expect session to session.

Session Frequency

Session frequency for anxiety generally mirrors depression protocols: twice weekly for 4-6 weeks during the acute phase, then weekly to monthly maintenance sessions based on how durable the response is.

Concurrent Therapy

Anxiety in particular benefits from integration with psychotherapy. Exposure-based therapy, such as CBT or ACT, conducted during the neuroplasticity window following ketamine sessions can accelerate reduction in avoidance behaviors. Some providers time therapy appointments to occur within 24-72 hours of a ketamine session. Discuss coordinating troche use with your prescribing provider; see our overview on working with your provider for what that coordination typically involves.

Evidence Overview

Clinical trials specifically targeting anxiety disorders with ketamine remain limited compared to treatment-resistant depression, but the evidence base is growing. A randomized, double-blind trial by Glue et al. (2017) found that subcutaneous ketamine reduced social anxiety symptoms significantly compared to placebo, with effects persisting for two weeks. Domany et al. (2019) tested 1 mg/kg oral ketamine three times weekly in a depression trial and found separation from placebo by week three, capturing comorbid anxiety improvement consistent with the broader pattern seen in this research.

Real-world outcomes data adds another data point. According to a 2023 analysis by Osmind, using outcomes data from the telehealth ketamine provider Mindbloom, 62.9 percent of patients who completed sublingual ketamine treatment achieved at least a 50 percent reduction in GAD-7 anxiety scores, with a 31.3 percent remission rate among that group. That analysis followed 1,247 completers out of 2,820 patients who initiated treatment, a completion rate that reflects how at-home ketamine programs currently operate rather than a controlled trial population, so it's best read as real-world signal rather than trial-level evidence.

On safety, a meta-analysis by Rosenblatt et al. followed 140 patients using oral and sublingual ketamine for up to three years and reported no significant adverse effects, tolerance, or substance misuse. Larger controlled trials specific to anxiety disorders are ongoing. The mechanistic basis for ketamine's anxiolytic effects is well supported by existing research, and clinical experience across numerous practices backs its use in treatment-resistant anxiety even as trial evidence continues to build. Background on depression's global prevalence and treatment gap, relevant given how often anxiety and depression co-occur, is available from the World Health Organization.